172 – Semaglutide Improves Cognitive Function in HIV, Effect Mediated by Decrease in Inflammation
Background People with HIV (PWH) are at higher risk for visceral adiposity and enhanced inflammation, and lower neurocognitive function when compared to controls without HIV. In a recent randomized placebo-controlled clinical trial of the GLP1 receptor agonist semaglutide, we demonstrated that PWH with lipohypertrophy had a decrease in weight, visceral adipose tissue, and in several…